Filippo Crea
doi : 10.1093/eurheartj/ehab628
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3411–3414
Sanjay Rajagopalan, MD, Robert B Jackson, PhD, Jagat Narula, MD
doi : 10.1093/eurheartj/ehab156
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3415–3417
Mark Nicholls
doi : 10.1093/eurheartj/ehab302
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3417–3419
Mark Nicholls
doi : 10.1093/eurheartj/ehab303
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3420–3421
Claudio Rapezzi, Gianfranco Sinagra, Marco Merlo, Roberto Ferrari
doi : 10.1093/eurheartj/ehab187
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3422–3424
Francesco Paneni, Massimo Volpe
doi : 10.1093/eurheartj/ehab435
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3425–3426
Michael Glikson, Jens Cosedis Nielsen, Mads Brix Kronborg, Yoav Michowitz, Angelo Auricchio, Israel Moshe Barbash, José A Barrabés, Giuseppe Boriani, Frieder Braunschweig, Michele Brignole, Haran Burri, Andrew J S Coats, Jean-Claude Deharo, Victoria Delgado, Gerhard-Paul Diller, Carsten W Israel, Andre Keren, Reinoud E Knops, Dipak Kotecha, Christophe Leclercq, Béla Merkely, Christoph Starck, Ingela Thylén, José Maria Tolosana, ESC Scientific Document Group
doi : 10.1093/eurheartj/ehab364
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3427–3520
Dominik Linz, Monika Gawa?ko, Prashanthan Sanders, John Penders, Na Li, Stanley Nattel, Dobromir Dobrev
doi : 10.1093/eurheartj/ehab467
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3521–3525
Dietary intake has been shown to change the composition of gut microbiota and some changes in microbiota (dysbiosis) have been linked to diabetes, hypertension, and obesity, which are established risk factors for atrial fibrillation (AF). In addition, intestinal dysbiosis generates microbiota-derived bioactive metabolites that might exert proarrhythmic actions. Although emerging preclinical investigations and clinical observational cohort studies suggest a possible role of gut dysbiosis in AF promotion, the exact mechanisms through which dysbiosis contributes to AF remain unclear. This Viewpoint article briefly reviews evidence suggesting that abnormalities in the intestinal microbiota play an important and little-recognized role in the pathophysiology of AF and that an improved understanding of this role may open up new possibilities in the management of AF.
Eduard Guasch, Stanley Nattel
doi : 10.1093/eurheartj/ehab473
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3526–3528
Jenny Bjerre, Simone Hofman Rosenkranz, Morten Schou, Christian J?ns, Berit Thornvig Philbert, Charlotte Larroudé, Jens Cosedis Nielsen, Jens Brock Johansen, Sam Riahi, Thomas Maria Melchior, Christian Torp-Pedersen, Mark Hlatky, Gunnar Gislason, Anne-Christine Ruwald
doi : 10.1093/eurheartj/ehab253
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3529–3537
Patients are restricted from driving following implantable cardioverter defibrillator (ICD) implantation or shock. We sought to investigate how many patients are aware of, and adhere to, the driving restrictions, and what proportion experience an ICD shock or other cardiac symptoms while driving.
Harry J G M Crijns, Kevin Vernooy
doi : 10.1093/eurheartj/ehab490
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3538–3540
Giulio Francesco Romiti, Bernadette Corica, Eugenia Pipitone, Marco Vitolo, Valeria Raparelli, Stefania Basili, Giuseppe Boriani, Sergio Harari, Gregory Y H Lip, Marco Proietti, the AF-COMET International Collaborative Group
doi : 10.1093/eurheartj/ehab453
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3541–3554
Prevalence of chronic obstructive pulmonary disease (COPD) in atrial fibrillation (AF) patients is unclear, and its association with adverse outcomes is often overlooked. Our aim was to estimate the prevalence of COPD, its impact on clinical management and outcomes in patients with AF, and the impact of beta-blockers (BBs) on outcomes in patients with COPD.
James A Reiffel
doi : 10.1093/eurheartj/ehab366
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3555–3557
Yen-Nien Lin, Thassio Mesquita, Lizbeth Sanchez, Yin-Huei Chen, Weixin Liu, Chang Li, Russell Rogers, Yizhou Wang, Xinling Li, Di Wu, Rui Zhang, Ahmed Ibrahim, Eduardo Marb?n, Eugenio Cingolani
doi : 10.1093/eurheartj/ehab419
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3558–3571
Arrhythmogenic cardiomyopathy (ACM) is characterized by progressive loss of cardiomyocytes, and fibrofatty tissue replacement. Extracellular vesicles (EVs) secreted by cardiosphere-derived cells, immortalized, and engineered to express high levels of ?-catenin, exert anti-inflammatory, and anti-fibrotic effects. The aim of the current study was to assess efficacy of EVs in an ACM murine model.
Cristina Basso, Tania Zaglia, Kalliopi Pilichou
doi : 10.1093/eurheartj/ehab512
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3572–3574
Ping-Hao Chiang, Yung-Chih Hsu, James Cheng-Chung Wei
doi : 10.1093/eurheartj/ehab459
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Page 3575
Huei-Kai Huang, Yu-Kang Tu, Ching-Hui Loh
doi : 10.1093/eurheartj/ehab461
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Pages 3576–3577
Shunsuke Sakai, Akira Sato, Tomoya Hoshi, Masaki Ieda
doi : 10.1093/eurheartj/ehaa991
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Page 3525
Francesca Cortese, Michelle Magli, Serena Di Marino
doi : 10.1093/eurheartj/ehaa1001
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Page 3578
Tomohisa Nakamura, Makoto Hyodo, Kenichiro Murata, Hiroaki Miyazaki, Kenji Ando
doi : 10.1093/eurheartj/ehaa1045
European Heart Journal, Volume 42, Issue 35, 14 September 2021, Page 3579
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟